VIFOR-PHARMA
21.12.2021 07:02:12 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
85% of the more than 1,000 patients with either high risk of hyperkalemia or active hyperkalemia were able to be optimized to guideline recommended, life-saving RAASi treatment, including mineralocorticoid receptor antagonists, with Veltassa® during the run-in phase of the study. This shows that the gap between guideline recommendations and real-world practice regarding the use of RAASi can be addressed with Veltassa® . Veltassa® was generally well tolerated and without unexpected safety findings. Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.
“We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “RAASi therapy saves lives and delays disease progression, but unfortunately many patients with heart failure are insufficiently treated due to risk of hyperkalemia. Hyperkalemia is a serious condition associated with life-threatening consequences. These data support an effective management of chronic hyperkalemia in heart failure patients on optimal RAASi therapy with Veltassa® . We look forward to presenting the detailed data to the scientific community in the first half of 2022.”
“This trial makes a significant contribution to the growing body of evidence showing the importance to use Veltassa® to enable RAASi and ensures optimal treatment in a high-risk population”, commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”
Vifor Pharma continues to support several data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to drive evidence-based care using Veltassa® in chronic kidney disease and heart failure patients.
About the DIAMOND trial
This global, multicenter, double-blind, placebo controlled study was designed to evaluate the potential role of Veltassa®
in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa®
in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyclic Materials Appoints Former Siemens and Alcoa CEO Klaus Kleinfeld to Board of Directors20.5.2026 14:30:00 CEST | Press release
Dr. Klaus Kleinfeld’s proven leadership at two Fortune 500 public companies will strengthen the company’s global expansion Cyclic Materials, the rare earth recycling company enabling domestic circular supply chain for critical materials around the world, today announced the appointment of Dr. Klaus Kleinfeld to its Board of Directors. Dr. Kleinfeld brings decades of experience leading global industrial and advanced manufacturing businesses, including serving as CEO of two Fortune 500 companies – Siemens AG and Alcoa. His experience growing complex international operations, navigating global markets, and leading large industrial transformations will support Cyclic Materials’ industrial expansion to meet an accelerating global demand. An internationally recognized executive, investor, and entrepreneur, Dr. Kleinfeld has advised multiple U.S. Presidents and global leaders on industrial competitiveness, technology, and economic development. “Cyclic Materials is scaling a strategically vita
HTEC and Motion Applied: Collaboration Built on Performance, Precision, and Innovation20.5.2026 14:18:00 CEST | Press release
HTEC, a global AI-first engineering and digital product development company, and Motion Applied are expanding their collaboration following a successful track record in developing advanced solutions across multiple industries. Motion Applied delivers engineering and technology solutions in motorsport, electrification and transportation, bringing 35 years of top-tier motorsport heritage and race-honed engineering excellence to the development of high-performance systems and their application beyond the track. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520285726/en/ HTEC, a global AI-first engineering and digital product development company, and Motion Applied are expanding their collaboration following a successful track record in developing advanced solutions for the motorsport and transportation industry. The two companies have worked closely on complex engineering initiatives, contributing to the advancement of high
Ennov Announces Strategic Growth Investment from Bregal Sagemount and Ardian20.5.2026 14:00:00 CEST | Press release
Ennov (the “Company”), a global provider of end-to-end regulatory, quality, and clinical software solutions for life sciences and healthcare companies, today announced a strategic growth investment led by Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, with participation from Ardian, a global private investment firm. The investment will support the Company’s continued expansion, with a focus on AI innovation, global go-to-market acceleration, and scaling its product offering. Founded and headquartered in Paris, Ennov provides a unified compliance platform that serves as a centralized system of record for global life sciences organizations. The platform supports the management of content and data across key domains, including Regulatory, Quality, Commercial, Clinical, and Pharmacovigilance. Its integrated architecture and unified data model enable faster deployment, improved user adoption, consistent compliance, and AI-driven efficiency across global operat
TreviPay Research Tracks the Evolution of B2B Buyer Expectations as AI Reshapes the Purchasing Process20.5.2026 14:00:00 CEST | Press release
New global study finds 73% of B2B buyers use AI in purchasing workflows while demand for invoice terms and consistent payment experiences reaches a three-year high New research from TreviPay, a global B2B payments infrastructure partner, found 88% of B2B buyers report high loyalty to their suppliers, consistent with TreviPay’s 2023 research. In 2026, buyers now place greater decision power on how efficiently and consistently suppliers deliver across the purchasing, payment and invoicing experience, meaning their loyalty is dependent on how well a supplier can execute. TreviPay’s latest report, The Evolution of the B2B Buyer, builds on the company’s 2023 B2B buyer research and examines how expectations have evolved across payments, onboarding, invoice terms, automation and supplier relationships. Key findings include:AI integration and digital maturity are reshaping purchasing. Seventy-three percent of buyers now use AI in purchasing workflows, showing automation has moved from explorat
Thales Announces Strategic Partnership with Google Cloud to Launch a New Sovereign Cloud in Germany20.5.2026 13:54:00 CEST | Press release
Thales and Google Cloud have signed a landmark partnership to launch a new European sovereign cloud offering in Germany, delivering advanced cloud capabilities to customers while keeping their data confidential, secure and fully sovereign. This solution will live on dedicated infrastructure that will be managed and operated by a new German entity, which Thales will fully own and control. This offering is designed to meet the stringent digital sovereignty and regulatory requirements of German public sector organizations and highly regulated industries, and meet Germany's new C3A framework criteria. It is available in Preview now and aims for General Availability by the end of 2026. By establishing this new sovereign region alongside PREMI3NS by S3NS, a Thales subsidiary, this new partnership marks an industry-first: a pan-European, geo-redundant, sovereign cloud offering that delivers a unique cross-border disaster recovery solution in Europe for Europe. Thales, a global leader in high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom